NCT03561870View on ClinicalTrials.gov

Olaparib in Recurrent IDH-mutant Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

November 8, 2021

Study Completion Date

November 24, 2021

Conditions
Recurrent IDHMutant High Grade Glioma
Interventions
DRUG

Olaparib 150 MG

Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity

Trial Locations (1)

Unknown

Hospices Civils de Lyon, Bron

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03561870 - Olaparib in Recurrent IDH-mutant Glioma | Biotech Hunter | Biotech Hunter